MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma - Trial NCT06414148
Access comprehensive clinical trial information for NCT06414148 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peter MacCallum Cancer Centre, Australia and is currently Not yet recruiting. The study focuses on Relapsed/Refractory Large B-cell Lymphoma. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peter MacCallum Cancer Centre, Australia
Timeline & Enrollment
Phase 2
May 07, 2024
May 01, 2028
Primary Outcome
The efficacy of Epcor-only (epcoritamab alone) or Epcor-R2 (epcoritamab, lenalidomide and rituximab) consolidation as assessed by conventional (Lugano 2014) response criteria at month 12 after the CART infusion
Summary
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to
 evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab,
 lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients
 that have responded by conventional criteria but who are at high risk of progression by
 virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour
 DNA (ctDNA) assay.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06414148
Non-Device Trial